EPISODE · May 9, 2025 · 6 MIN
Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals
from BiotechTV - News · host BiotechTV
Interim CEO Magda Jonikas describes Mosaic's platform and the rationale behind these two targets the company has licensed in.
Embed this episode
NOW PLAYING
Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals
0:00
6:59
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 6 minutes long.
When was this BiotechTV - News episode published?
This episode was published on May 9, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!